HEALTHTHE HILL
FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists
The FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted to add peptides like BPC-157, KPV, TB-500, and MOTS-c to the list of substances compounding pharmacies can make, despite opposition from FDA scientists over concerns about their unproven benefits.
Mentioned
Related Signal
Adjacent reporting
- FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list
- FDA panel narrowly backs unapproved peptide drug touted by Joe Rogan and other influencers
- FDA panel narrowly backs unapproved peptide drug touted by Joe Rogan and other influencers
- FDA Panel Narrowly Backs Lifting Restrictions on Peptides Backed by RFK Jr.